ArticleCancer research communications2026
DGAT1 Drives Racially Divergent Fibroblast Activation via ERK1/2-Dependent Tumorigenic Signaling in Prostate Cancer.
Article in Cancer research communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
13 authors.
Funding
Abstract
Lethal prostate cancer disproportionately affects African American (AA) men, who experience a higher incidence and earlier onset compared with European American (EA) men, reflecting a persistent biological and clinical disparity. Recent studies have implicated race-associated differences in lipid metabolic reprogramming as key contributors to this disparity. We recently identified carcinoma-associated fibroblasts (CAF) as a major stromal component that mediates racial disparities in tumor progression. Here, we demonstrate that lipid-laden CAFs from AA patients (AACAF) display enhanced protumorigenic properties compared with CAFs from EA patients (EACAF). Lipid droplet (LD) biogenesis and storage analysis revealed a robust diacylglycerol O-acyltransferase 1 (DGAT1) enzyme-dependent LD accumulation in AACAF. Ectopic DGAT1 expression in benign fibroblasts induced CAF markers' (FAP1 and αSMA) expression linked to fibroblast activation, altered the secretome, and significantly enhanced prostate cancer cells' growth in vivo. Integrative transcriptomic and secretome analyses identified novel DGAT1-regulated genes involved in CAF linked to metabolism, cell-cell communication, motility, and angiogenesis, mediated mainly through ERK1/2 signaling activation. Pharmacologic DGAT1 inhibition suppressed these pathways and elicited racially distinct regulation of tumor-promoting mediators, including BDNF, VEGF, and TSP1. Mechanistic experiments show that functionally, lipid-laden CAFs from AA patients exhibit increased fibroblast activation and a secretory phenotype with greater protumor activity compared with CAFs from EA patients. Collectively, these findings reveal that DGAT1 is a pivotal enzymatic regulator of fibroblast activation and lipid-driven remodeling in the prostate cancer tumor microenvironment of AA men. Targeting DGAT1 represents a promising strategy to disrupt metabolic-stromal cross-talk and mitigate race-associated disparities in prostate cancer progression. SIGNIFICANCE: This study highlights DGAT1-driven lipid accumulation in CAFs from AA patients with prostate cancer as a key driver of fibroblast activation and tumor-promoting roles contributing to racial disparities. Targeting DGAT1 disrupts lipid-mediated cancer-stroma interactions, offering a new therapeutic strategy to reduce aggressive prostate cancer in AA men.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.